B-cell Lymphoma
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.
Detailed description
This is a prospective open-label, single-arm clinical study to evaluate the safety, tolerability of BAFF-R CAR-T cells in adult subjects with CD19-negative relapsed or refractory B-Cell Lymphoma. The study plans to explore across three dose levels (1.00 × 10\^6, 3.00 × 10\^6, 9.00 × 10\^6 CAR+ T cells/kg), and 6.00×10\^8 CAR+T cells as maximum dose, aiming to evaluate the safety, tolerability of BAFF-R CAR-T cells in CD19-negative relapsed or refractory B-Cell Lymphoma, explore Maximum Tolerated Dose (MTD) and determine the recommended dose for Phase II. Besides, efficacy, pharmacokinetics and persistence profile of CAR-T cells are also study objectives.
Interventions
BIOLOGICALBAFF-R CAR-T cells
BAFF-R CAR-T cells, single intravenous infusion
Sponsors
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Subjects voluntarily participate in clinical research and sign informed consent. * 2\. Subjects with CD19-negative relapsed or refractory B-cell lymphoma: a) failure to achieve CR after 6 cycles, or PR after 3 cycles, of first-line therapy, or achieve CR after first-line therapy but relapse within 12 months; b) achieve CR after systemic treatment, but are refractory or relapsed, and no plan to transplant, or prepare for transplantation but cannot meet transplantation criteria after second-line therapy; c) not achieve CR after at least two courses of second-line treatment (including autologous stem cell transplantation). * 3\. Expected survival ≥ 3 months. * 4\. BAFF-R expression are detected on tumor cells of subjects by flow cytometry or immunohistochemistry. * 5\. ECOG score ≤ 2. * 6\. Subjects with adequate organ functions prior to enrollment, meet the following laboratory values: * Renal function: serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m² * Hepatic function: Serum alanine aminotransferase (ALT) ≤ 5 × age-specific ULN and total bilirubin ≤ 2.0 mg/dL, except in subjects with Gilbert-Meulengracht syndrome. If total bilirubin ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN, subjects with Gilbert-Meulengracht syndrome are included. * Pulmonary reserve: ≤ Grade 1 dyspnea and oxygen saturation \>95% on room air. * 7\. Stable hemodynamics and left ventricular ejection fraction (LVEF) ≥ 45 % assessed by echocardiography or multi-gated radionuclide angiography (MUGA). * 8\. Adequate bone-marrow reserve without blood transfusion as defined by: * Absolute neutrophil count (ANC) ≥ 1 x 10\^9/L. * Absolute lymphocyte count (ALC) ≥ 0.1 x 10\^9/L. * Platelets ≥ 50 x 10\^9/L. * Hemoglobin \>80g/L. * 9\. In the investigator's judgment, subjects' general condition and all biochemical values are either normal or sufficiently compensated to receive lymphodepletion and CAR-T cell therapy.
Exclusion criteria
* 1\. Women who are pregnant or breastfeeding, or planned pregnancy within 6 months. * 2\. Infectious disease(HIV, Active Tuberculosis ect.). * 3\. Active infection: hepatitis B, hepatitis C. * 4\. Abnormal vital signs or refuse to receive examination. * 5\. Subjects with psychiatric or psychological disorders are unable to complete treatment or efficacy assessment. * 6\. History of severe hypersensitivity or known hypersensitivity to IL-2. * 7\. Systemic or local severe infection requiring antimicrobial therapy. * 8\. Significant dysfunction of vital organs (heart, lung, brain, kidney, etc.), or in the investigator's judgment, subjects are unable to be enrolled with any other condition.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose-limiting toxicity (DLT) | 1 month after injection | Dose-limiting toxicity for each subject |
| AE/SAE | 1 month, 3 months, 6 months, 12 months after injection | Incidence and severity of adverse events (AE), and serious adverse event (SAE) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | 1 month, 3 months, 6 months, 9 months, 12 months after injection | Proportion of patients whose tumor volume has reached a predetermined value and can maintain a minimum time limit, including complete response and partial response patients. |
| Overall survival (OS) | 1 month, 3 months, 6 months, 9 months, 12 months after injection | Defined as the time from the date of first infusion to death due to any cause |
| Duration of response (DOR) | 1 month, 3 months, 6 months, 9 months, 12 months after injection | The time from the date of first response (PR or better) to the date of disease progression after infusion |
| Progression-free survival (PFS) | 1 month, 3 months, 6 months, 9 months, 12 months after injection | The time from first infusion to the date of progression or death. |
Countries
China
Contacts
CONTACTXiao Ma
Outcome results
None listed